Project Grant HT9425261E289
Award Date 9/1/26
Completion Date 8/31/30
Dollars Obligated $4.2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $723,699 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective July 15, 2026, through July 14, 2029. The award supports research aimed at optimizing immunotherapy for pediatric solid tumors. Based on DHA's funding portfolio and Dana-Farber's research capabilities, this project likely involves mechanistic studies and...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. (DFCI) received a $1,014,596 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) on July 15, 2026. The award, which extends through July 14, 2029, supports research to optimize immunotherapy approaches for pediatric solid tumors. This research initiative aligns with the DHA's portfolio of clinical trials and translational research addressing Service Member...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. (DFCI) received a $1.424 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded August 1, 2025, with a performance period through July 31, 2029. The award supports research to expand the targetable tumor antigen repertoire of renal cell carcinoma, positioning the work within DHA's broader portfolio of hypothesis-driven biomedical research...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. (DFCI) received a $1.12M Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2026, through August 31, 2030. The award supports resource development and research to improve clinical outcomes for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematologic malignancy. As a leading academic cancer research institution affiliated...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $559,999 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to support the development of novel digenic combination therapies for pancreatic cancer treatment. The award period runs from September 1, 2026 through August 31, 2028. This funding supports basic and applied biomedical research addressing medical needs relevant to the military population,...
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $1,099,614 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective June 1, 2026 through May 31, 2030. The award funds research to define a Retinoblastoma (RB) functional subtype of endometrial cancer. This research initiative aligns with the DHA's mission to support basic and applied biomedical research addressing Service Member...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $1.1 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective June 1, 2026, through May 31, 2030. The project, titled "LISTEN: Augmenting and Facilitating Communication in Brain Tumor Patients with Aphasia," supports biomedical research addressing Service Member health and military-relevant medical conditions. The four-year...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded Trustees of Boston University a $990,016 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective April 1, 2026, through March 31, 2029. The award supports research on "Biomaterial Strategies to Improve Specificity and Efficacy of CAR T Cell Therapy for Breast Cancer," conducted at the university's Boston, Massachusetts campus. This three-year initiative focuses on developing...
- The U.S. Defense Health Agency has awarded a $712,000 Project Grant through the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) in Boston, MA. The 2-year grant, with a period of performance from July 1, 2024 to June 30, 2026, will support a longitudinal study to identify mechanisms of treatment resistance in rhabdomyosarcoma through circulating tumor DNA analysis. As a not-for-profit hospital and cancer research...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded Boston Children's Hospital a $559,998 Project Grant effective July 1, 2026, through June 30, 2028, under the Military Medical Research and Development program (CFDA 12.420). The award funds basic and applied biomedical research titled "Defining the Cell of Origin and Mechanisms of Initiation for Pediatric Melanoma," conducted at the institution's Boston, Massachusetts facility. This project contributes to the...